홍역, 볼거리, 풍진(MMR) 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is witnessing strong expansion due to rising disease incidence, growing immunization coverage, and sustained government support worldwide. According to Fortune Business Insights, the global MMR vaccines market size was valued at USD 5.17 billion in 2025. The market is projected to grow from USD 5.59 billion in 2026 to USD 14.43 billion by 2034, registering a CAGR of 12.59% during the forecast period. North America dominated the global market with a share of 38.02% in 2025, supported by robust immunization programs and high vaccine uptake.

Measles, mumps, and rubella are highly contagious and potentially life-threatening viral diseases. MMR vaccines are combination vaccines containing live attenuated viruses, administered in two doses-typically at 12 months and again at 4 years of age. The high potency, strong immunogenic response, and long-term protection offered by these vaccines have made them essential components of national immunization schedules across multiple countries.

Market Dynamics

Market Drivers

Rising government initiatives and immunization programs are major drivers of the MMR vaccines market. Countries such as the U.S. and India have incorporated MMR vaccines into their National Immunization Programs (NIP), ensuring free or subsidized access. Support from international organizations such as WHO, UNICEF, and Gavi has significantly expanded vaccine coverage. According to the CDC, as of January 2025, one dose of the MMR vaccine is 93.0% effective against measles, 72% against mumps, and 97% against rubella, reinforcing strong confidence in vaccine effectiveness.

Market Restraints

Vaccine hesitancy remains a key restraint limiting market growth. Factors such as misinformation, religious beliefs, and fear of side effects reduce vaccine acceptance. Reports published in 2023 highlighted parental concerns regarding post-vaccination fever and injection-site pain, which continue to delay immunization in certain populations.

Market Opportunities

Technological advancements, particularly the development of microarray patches (MAPs), offer promising growth opportunities. These needle-free, thermostable delivery systems improve patient compliance and simplify vaccine administration, especially in low- and middle-income countries. UNICEF and WHO have actively supported MAP development, indicating strong future potential.

Market Challenges

Cold chain maintenance remains a critical challenge. MMR vaccines are highly temperature-sensitive, and improper storage or transportation can lead to vaccine wastage and reduced efficacy. Weak cold chain infrastructure in remote regions continues to hinder optimal market expansion.

Market Trends

A key trend shaping the market is the rise in public-private partnerships. Collaboration between governments, NGOs, and pharmaceutical companies is improving vaccine accessibility, strengthening supply chains, and addressing immunization gaps. Increasing measles resurgence globally has further intensified coordinated immunization efforts.

Segmentation Analysis

By Type

The combination vaccine segment dominated the market in 2024 due to convenience, cost-effectiveness, and reduced injection burden. Products such as M-M-R II and PRIORIX support higher patient compliance. The standalone segment maintained a notable share due to disease-specific usage.

By Product

M-M-R II held the largest market share in 2024, driven by decades-long usage and widespread inclusion in national immunization programs. PRIORIX is expected to grow at a strong pace due to U.S. FDA approval and licensing across more than 100 countries.

By Route of Administration

The subcutaneous route dominated the market in 2024, supported by regulatory recommendations and patient comfort. The intramuscular segment also held a significant share due to strong immunogenicity and expanded approvals.

By Age Group

The pediatric segment led the market owing to mandatory childhood vaccination schedules. The adult segment is growing steadily as awareness increases among unvaccinated or partially vaccinated adults.

By Distribution Channel

Government suppliers accounted for the largest share in 2024 due to large-scale procurement for national immunization programs. Hospital and retail pharmacies are expected to grow significantly with expanding vaccination access points.

Regional Outlook

North America generated revenues of USD 1.97 billion in 2025 and USD 2.15 billion in 2026, driven by high vaccination coverage and strong public health infrastructure.

Europe maintained a significant share due to mandatory two-dose schedules across EU/EEA countries.

Asia Pacific is witnessing the fastest growth, supported by large population bases and government-funded vaccination programs, particularly in India.

Latin America and the Middle East & Africa are growing steadily with increasing awareness and improved vaccine access.

Competitive Landscape

The market is led by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd., supported by strong R&D pipelines and global distribution networks. Other prominent players include Indian Immunologicals Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, and Biological E. Limited.

Conclusion

In conclusion, the global measles, mumps, rubella (MMR) vaccines market is set for robust growth from 2025 to 2034, expanding from USD 5.17 billion in 2025 to USD 14.43 billion by 2034. Strong government initiatives, high vaccine efficacy, and expanding immunization coverage are key growth drivers. However, vaccine hesitancy and cold chain challenges remain critical concerns. Continued innovation, public-private collaboration, and investment in advanced delivery technologies will be essential to sustaining long-term market growth.

Segmentation By Type

• Standalone
• Combination

By Product

• M-M-R II
• PRIORIX
• M-M-RvaxPro
• Tresivac
• Others

By Route of Administration

• Intramuscular
• Subcutaneous
• Others

By Age Group

• Adult
• Pediatric

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Overview: Immunization Coverage, By Key Countries
• 4.4. Technological Advancements in the MMR Vaccines
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Standalone
  • 5.1.2. Combination
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. M-M-R II
  • 5.2.2. PRIORIX
  • 5.2.3. M-M-RvaxPro
  • 5.2.4. Tresivac
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Intramuscular
  • 5.3.2. Subcutaneous
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Pediatrics
  • 5.4.2. Adults
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital & Retail Pharmacies
  • 5.5.2. Government Suppliers
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Standalone
  • 6.1.2. Combination
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. M-M-R II
  • 6.2.2. PRIORIX
  • 6.2.3. M-M-RvaxPro
  • 6.2.4. Tresivac
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Intramuscular
  • 6.3.2. Subcutaneous
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Pediatrics
  • 6.4.2. Adults
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital & Retail Pharmacies
  • 6.5.2. Government Suppliers
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Standalone
  • 7.1.2. Combination
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. M-M-R II
  • 7.2.2. PRIORIX
  • 7.2.3. M-M-RvaxPro
  • 7.2.4. Tresivac
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Intramuscular
  • 7.3.2. Subcutaneous
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Pediatrics
  • 7.4.2. Adults
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital & Retail Pharmacies
  • 7.5.2. Government Suppliers
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Standalone
  • 8.1.2. Combination
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. M-M-R II
  • 8.2.2. PRIORIX
  • 8.2.3. M-M-RvaxPro
  • 8.2.4. Tresivac
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Intramuscular
  • 8.3.2. Subcutaneous
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Pediatrics
  • 8.4.2. Adults
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital & Retail Pharmacies
  • 8.5.2. Government Suppliers
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Standalone
  • 9.1.2. Combination
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. M-M-R II
  • 9.2.2. PRIORIX
  • 9.2.3. M-M-RvaxPro
  • 9.2.4. Tresivac
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Intramuscular
  • 9.3.2. Subcutaneous
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Pediatrics
  • 9.4.2. Adults
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital & Retail Pharmacies
  • 9.5.2. Government Suppliers
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Standalone
  • 10.1.2. Combination
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. M-M-R II
  • 10.2.2. PRIORIX
  • 10.2.3. M-M-RvaxPro
  • 10.2.4. Tresivac
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Intramuscular
  • 10.3.2. Subcutaneous
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Pediatrics
  • 10.4.2. Adults
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital & Retail Pharmacies
  • 10.5.2. Government Suppliers
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Serum Institute of India Pvt. Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Indian Immunologicals Limited
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Zydus Lifesciences Limited
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Takeda Pharmaceutical Company Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. BIOLOGICAL E. LIMITED
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Invivyd, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Daiichi Sankyo Company, Limited
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)